Skip to main content
. 2022 Apr 20;8:51. doi: 10.1038/s41523-022-00415-z

Fig. 2. Survival based on chemotherapy use in stage I and II patients.

Fig. 2

Recurrence-free (RFS) and breast cancer-specific survival (BCSS) in stage-I and II patients based on whether they received chemotherapy or not (a RFS in stage-I patients for chemotherapy, log-rank test p-value 0.615; b RFS in stage-II patients for chemotherapy, log-rank test p-value 0.085; c BCSS in stage-I patients for chemotherapy, log-rank test p-value 0.525; d BCSS in stage-II patients for chemotherapy, log-rank test p-value 0.166).